Insmed Inc
INSM194.390USD
+0.700+0.36%
收盤 11/12, 16:00（美東）報價延遲15分鐘
41.32B總市值
虧損本益比TTM
關於 Insmed Inc 公司
Insmed Incorporated 是一家全球生物製藥公司。該公司正在推進一系列已獲批准和中後期研究藥物以及藥物發現。其先進的項目涉及肺部和炎症疾病，包括一種在美國、歐洲和日本獲批的治療慢性、衰弱性肺病的療法。該公司的臨牀前研究項目涵蓋廣泛的技術和模式，包括基因治療、人工智能驅動的蛋白質工程、蛋白質製造、RNA 末端連接和合成救援。其首款商業產品 ARIKAYCE（阿米卡星脂質體吸入混懸液）用於治療鳥分枝桿菌複合體 (MAC) 肺病，作爲聯合抗菌藥物方案的一部分，用於治療治療選擇有限或沒有替代治療方案的成人患者。其產品線包括臨牀階段項目、brensocatib、TPIP 和 INS1201 以及臨牀前研究項目。
Insmed Inc簡介
公司代碼INSM
公司名稱Insmed Inc
上市日期Feb 15, 1991
CEOMr. William H. (Will) Lewis, J.D.
員工數量1271
證券類型Ordinary Share
年結日Feb 15
公司地址700 Us Highway 202/206
城市BRIDGEWATER
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編08807
電話19089779900
網址https://insmed.com/
公司代碼INSM
上市日期Feb 15, 1991
CEOMr. William H. (Will) Lewis, J.D.
Insmed Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
402.00K
-2.59%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
308.40K
-3.70%
Dr. Clarissa Desjardins, Ph.D.
Dr. Clarissa Desjardins, Ph.D.
Independent Director
Independent Director
53.84K
+10.37%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
53.77K
-52.74%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
50.16K
+11.22%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
25.55K
-49.45%
Dr. Martina Flammer, M.D.
Dr. Martina Flammer, M.D.
Chief Medical Officer
Chief Medical Officer
4.27K
-66.30%
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Chief Financial Officer
Chief Financial Officer
239.00
-98.89%
Ms. Elizabeth Mckee Anderson
Ms. Elizabeth Mckee Anderson
Independent Director
Independent Director
--
--
Ms. S. Nicole Schaeffer
Ms. S. Nicole Schaeffer
Chief People Strategy Officer
Chief People Strategy Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
402.00K
-2.59%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
308.40K
-3.70%
Dr. Clarissa Desjardins, Ph.D.
Dr. Clarissa Desjardins, Ph.D.
Independent Director
Independent Director
53.84K
+10.37%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
53.77K
-52.74%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
50.16K
+11.22%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
25.55K
-49.45%
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
暫無數據
地區USD
名稱
營收
佔比
US
68.68M
0.00%
Japan
30.67M
0.00%
Europe and rest of worldld
8.06M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.33%
JP Morgan Asset Management
9.08%
Darwin Global Management Ltd
9.07%
T. Rowe Price Associates, Inc.
5.19%
BlackRock Institutional Trust Company, N.A.
4.22%
其他
63.12%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.33%
JP Morgan Asset Management
9.08%
Darwin Global Management Ltd
9.07%
T. Rowe Price Associates, Inc.
5.19%
BlackRock Institutional Trust Company, N.A.
4.22%
其他
63.12%
股東類型
持股股東
佔比
Investment Advisor
50.22%
Hedge Fund
26.60%
Investment Advisor/Hedge Fund
21.62%
Research Firm
3.02%
Bank and Trust
1.53%
Family Office
1.08%
Sovereign Wealth Fund
0.91%
Pension Fund
0.86%
Individual Investor
0.66%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
895
217.27M
101.89%
+3.61M
2025Q2
807
207.14M
108.81%
-3.07M
2025Q1
804
211.64M
111.66%
-239.74K
2024Q4
767
205.04M
113.32%
-2.57M
2024Q3
712
200.94M
112.58%
+1.71M
2024Q2
657
186.57M
112.00%
+21.58M
2024Q1
564
156.59M
105.42%
-6.86M
2023Q4
544
155.47M
105.16%
-6.81M
2023Q3
515
153.95M
107.69%
-8.46M
2023Q2
506
152.37M
106.87%
-10.75M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
17.60M
8.33%
-627.46K
-3.44%
Jun 30, 2025
JP Morgan Asset Management
12.98M
6.14%
+7.57M
+140.01%
Jun 30, 2025
Darwin Global Management Ltd
19.34M
9.15%
+3.95M
+25.63%
Jun 30, 2025
T. Rowe Price Associates, Inc.
11.08M
5.24%
-1.69M
-13.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.99M
4.26%
-4.01M
-30.83%
Jun 30, 2025
Baker Bros. Advisors LP
7.71M
3.65%
+2.33M
+43.35%
Jun 30, 2025
Capital International Investors
7.48M
3.54%
+280.37K
+3.89%
Jun 30, 2025
Capital World Investors
7.68M
3.63%
+11.60K
+0.15%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.05M
2.39%
+1.71M
+51.07%
Jun 30, 2025
State Street Investment Management (US)
4.28M
2.02%
-1.47M
-25.57%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco Dorsey Wright Healthcare Momentum ETF
4.62%
Franklin Genomic Advancements ETF
4.55%
VanEck Biotech ETF
4.43%
ProShares Ultra Nasdaq Biotechnology
3.14%
Invesco Nasdaq Biotechnology ETF
3.08%
First Trust Health Care Alphadex Fund
3.03%
iShares Biotechnology ETF
2.82%
Virtus LifeSci Biotech Products ETF
2.48%
Goldman Sachs Hedge Industry VIP ETF
2.32%
Pinnacle Focused Opportunities ETF
2.12%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
佔比4.62%
Franklin Genomic Advancements ETF
佔比4.55%
VanEck Biotech ETF
佔比4.43%
ProShares Ultra Nasdaq Biotechnology
佔比3.14%
Invesco Nasdaq Biotechnology ETF
佔比3.08%
First Trust Health Care Alphadex Fund
佔比3.03%
iShares Biotechnology ETF
佔比2.82%
Virtus LifeSci Biotech Products ETF
佔比2.48%
Goldman Sachs Hedge Industry VIP ETF
佔比2.32%
Pinnacle Focused Opportunities ETF
佔比2.12%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
